Brokerages expect Merus NV (NASDAQ:MRUS) to post sales of $7.57 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Merus’ earnings, with the lowest sales estimate coming in at $4.66 million and the highest estimate coming in at $10.47 million. Merus posted sales of $7.81 million in the same quarter last year, which suggests a negative year over year growth rate of 3.1%. The firm is scheduled to announce its next earnings results on Thursday, July 25th.

On average, analysts expect that Merus will report full year sales of $29.91 million for the current financial year, with estimates ranging from $18.62 million to $41.19 million. For the next financial year, analysts anticipate that the firm will post sales of $49.95 million, with estimates ranging from $18.62 million to $81.28 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Merus.

Merus (NASDAQ:MRUS) last posted its earnings results on Wednesday, April 3rd. The biotechnology company reported ($0.34) earnings per share for the quarter. Merus had a negative net margin of 75.71% and a negative return on equity of 38.79%. The firm had revenue of $9.67 million during the quarter.

Several analysts have recently weighed in on the company. BidaskClub downgraded Merus from a “hold” rating to a “sell” rating in a report on Thursday, May 9th. Guggenheim assumed coverage on Merus in a report on Friday, April 12th. They issued a “buy” rating and a $25.00 target price for the company. Wedbush reduced their target price on Merus from $34.00 to $25.00 and set an “outperform” rating for the company in a report on Friday, April 5th. Royal Bank of Canada raised Merus from a “sector perform” rating to an “outperform” rating and boosted their target price for the company from $18.00 to $23.00 in a report on Wednesday, April 3rd. Finally, Berenberg Bank assumed coverage on Merus in a research report on Wednesday, March 27th. They issued a “buy” rating and a $35.00 price target on the stock. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the stock. Merus presently has a consensus rating of “Hold” and a consensus price target of $23.00.

Merus stock opened at $13.90 on Monday. Merus has a fifty-two week low of $11.00 and a fifty-two week high of $26.74. The stock has a market capitalization of $307.14 million, a PE ratio of -7.55 and a beta of -0.05.

A number of hedge funds have recently modified their holdings of MRUS. Aquilo Capital Management LLC increased its position in Merus by 3.6% in the 3rd quarter. Aquilo Capital Management LLC now owns 1,295,713 shares of the biotechnology company’s stock valued at $25,577,000 after acquiring an additional 44,799 shares during the period. Morgan Stanley increased its position in Merus by 74.3% in the 3rd quarter. Morgan Stanley now owns 71,643 shares of the biotechnology company’s stock valued at $1,415,000 after acquiring an additional 30,538 shares during the period. Artal Group S.A. acquired a new position in Merus in the 4th quarter valued at about $2,886,000. Geode Capital Management LLC increased its position in Merus by 18.8% in the 4th quarter. Geode Capital Management LLC now owns 14,987 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 2,373 shares during the period. Finally, Squarepoint Ops LLC increased its position in Merus by 10.3% in the 4th quarter. Squarepoint Ops LLC now owns 11,800 shares of the biotechnology company’s stock valued at $165,000 after acquiring an additional 1,100 shares during the period. Hedge funds and other institutional investors own 52.13% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.

Read More: What are the components of an earnings report?

Get a free copy of the Zacks research report on Merus (MRUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.